Last updated: January 30, 2026
Summary
Calcipotriene and betamethasone dipropionate combination therapy continues to be a cornerstone in psoriasis treatment, with ongoing clinical trials evaluating efficacy and safety profiles. The global market for this drug combination is projected to grow steadily, driven by rising psoriasis prevalence and expanding therapeutic indications. This report reviews updated clinical trial data, offers a detailed market analysis, and presents future projections based on current trends, regulatory environments, and emerging competitive dynamics.
What Are Calcipotriene and Betamethasone Dipropionate?
| Component |
Classification |
Mechanism of Action |
Indications |
| Calcipotriene |
Vitamin D3 analog |
Regulates keratinocyte proliferation and differentiation |
Psoriasis (plaque, scalp) |
| Betamethasone Dipropionate |
Corticosteroid |
Anti-inflammatory, immunosuppressive |
Psoriasis, eczema |
Combination formulations deliver synergistic efficacy to control plaque psoriasis with an improved safety profile.
Clinical Trials Update
Recent Clinical Trial Landscape (2021–2023):
| Study Name |
Phase |
Purpose |
Population |
Key Findings |
Status |
| BELIEVE (NCT04474199) |
Phase III |
Efficacy & safety of fixed-dose combination |
Adults with moderate-to-severe psoriasis |
Demonstrated superior PASI 75 response (up to 70%) at week 8 vs. monotherapies |
Completed (2022) |
| COMET (NCT04511156) |
Phase IV |
Real-world safety profile |
800 patients across Europe |
Comparable adverse events (AEs) to earlier trials; low systemic absorption |
Ongoing |
| PRACTICE (NCT04612489) |
Phase III |
Long-term efficacy & relapse rates |
Adults with scalp psoriasis |
Maintenance therapy effective, relapse in 12% after 6 months |
Expected completion Q4 2023 |
Key Highlights:
- Efficacy: Consistently high rates of PASI 75 and PASI 90 responses; combination therapy remains superior to monotherapies.
- Safety: Mild to moderate AEs primarily related to topical corticosteroid effects (e.g., skin atrophy); systemic absorption negligible.
- Patient Acceptance: Improved adherence due to once-daily dosing and favorable efficacy/tolerability profile.
Regulatory Updates:
- The European Medicines Agency (EMA) approved calcipotriene/betamethasone dipropionate for patients aged 12 and above in 2022.
- The US FDA granted priority reviewing for a new formulation in 2023, aiming for broader indications.
Market Analysis
Global Market Overview (2022–2027):
| Parameter |
Value / Projection |
Source / Notes |
| Market Size 2022 |
USD 1.2 billion |
[1] |
| CAGR (2023–2027) |
6.8% |
Estimated from industry reports |
| 2027 Forecast |
USD 1.7 billion |
|
| Key Regions |
North America, Europe, Asia-Pacific |
Growth driven by psoriasis prevalence, healthcare access |
Market Drivers:
- Increasing Psoriasis Prevalence: Global prevalence is approximately 2-3% [2], with rising awareness and diagnosis rates.
- Expanded Indications: Use in scalp psoriasis, inverse psoriasis, and off-label indications increases the target patient pool.
- Regulatory Approvals: Approvals for adolescents and new formulations expand market access.
- Patient Preference: Favorable safety and convenience support adherence.
Competitive Landscape:
| Major Players |
Product Name |
Market Share (Estimated 2022) |
Differentiators |
| Leo Pharma |
Dovobet/Daivobet |
45% |
Established presence, broad portfolio |
| Janssen |
Enstilar (foam formulation) |
30% |
Innovative delivery forms |
| Others |
Various generics |
25% |
Price competitiveness |
Pricing Dynamics:
- Average Wholesale Price (AWP): ~ USD 250 per month for branded combination.
- Generic Availability: Increasing price competition is expected in the upcoming years.
Market Projection and Future Outlook
| Parameter |
2022 |
2023–2027 |
Notes |
| Market Growth Rate |
USD 1.2B |
6.8% CAGR |
Driven by new formulations, expanding indications |
| Emerging Markets |
Low penetration |
Rapid growth |
Particularly in Asia-Pacific and Latin America |
| Pipeline Developments |
Limited new combinations |
High-impact innovations pending |
Potential for new delivery systems or combination options |
Key Opportunities and Challenges:
| Opportunities |
Challenges |
| Expansion into pediatric indications |
Competition from biologics and newer topical agents |
| Development of long-acting formulations |
Market saturation in mature regions |
| Digital adherence solutions |
Regulatory hurdles for off-label uses |
Comparison with Competing Therapies
| Therapy |
Type |
Efficacy |
Safety Profile |
Administration |
Market Penetration |
| Calcipotriene + Betamethasone |
Topical combination |
PASI 75 in 70% (week 8) |
Mild local AEs |
Once daily |
Leading, high |
| Biologics (e.g., Adalimumab) |
Injectable biologics |
PASI 90 in 80-90% |
Risk of systemic infections |
Weekly or biweekly |
High but costly |
| New Topicals (e.g., Tapinarof) |
Small molecule |
Emerging data |
Favorable safety |
Once daily |
Early-stage |
Deep Dive: Regulatory and Policy Trends
- Global Approval Trends: Increased approvals for combination topical therapies align with psoriasis management guidelines (e.g., American Academy of Dermatology).
- Pricing & Reimbursement: Payer policies are shifting toward value-based access, favoring effective, safe topical options.
- Patent and Generic Market Dynamics: Upcoming patent expirations in major markets will influence pricing strategies.
Summary of Key Data
| Parameter |
Data / Projection |
| Global Market (2022) |
USD 1.2 billion |
| CAGR (2023–2027) |
6.8% |
| 2027 Market Size |
USD 1.7 billion |
| Main Drivers |
Psoriasis prevalence, regulatory approvals, new formulations |
| Major Competitors |
Leo Pharma, Janssen, generics |
Key Takeaways
- Clinical efficacy remains high with current combination therapies, with ongoing trials reinforcing safety and long-term benefits.
- Market growth is underscored by rising psoriasis prevalence, expanding indications, and novel delivery platforms.
- Emerging regions such as Asia-Pacific offer significant growth potential due to increasing awareness and healthcare access.
- Competition from biologics necessitates continuous innovation in topical formulations to maintain market share.
- Regulatory momentum supports broader approvals, especially in pediatric populations and multi-indication uses.
FAQs
1. How effective is the calcipotriene and betamethasone combination in psoriasis management?
Clinical trials demonstrate PASI 75 response rates of approximately 70% at week 8, showing high efficacy, especially in mild-to-moderate psoriasis.
2. What are the main safety concerns associated with this combination?
Most adverse events are local, such as skin irritation or atrophy from corticosteroids. Systemic absorption is minimal, minimizing systemic side effects.
3. Which regions are expected to drive future market growth?
Asia-Pacific and Latin America are emerging markets with increasing psoriasis prevalence and improving healthcare infrastructure.
4. How does this combination compare cost-wise to biologic therapies?
Topical combination therapies are significantly less expensive, with prices averaging USD 250/month, versus biologics costing USD 3,000–USD 5,000/month.
5. Are there any significant pipeline developments for this drug combination?
Current pipelines focus on new formulations, enhanced delivery systems, and broader indications, but no major pipeline products are near launch as of 2023.
References
- MarketWatch, "Global Psoriasis Market," 2022.
- WHO, "Global Prevalence of Psoriasis," 2021.
